CSL

CSL

Thu, 07/02/2008 - 01:51

Stock Code

CSL

Stock Exchange

Australian Securities Exchange

CSL is a biopharmaceutical conglomerate that develops, manufactures and markets products which act as treatment or prevention against human medical conditions. CSL operates globally through subsidiaries of CSL Behring, CSL Bioplasma and CSL Biotherapies. The company operates in 27 countries, with major manufacturing facilities in Australia, Germany, New Zealand, Switzerland and the US and has over 9000 employees.

CSL business operations have three separate divisions: pharmaceuticals and vaccines; plasma products; and research and development.

CSL Pharmaceuticals and Vaccines

Top 3 Best Performers on the ASX This Week


Ansell (ANN), an Australia based company that operates in the gloves and other protective product industry was the best performer of the week in ASX100 with a gain of 11.6 percent or $1.20 closing the week at $11.52 (market capitalisation: $1560 million).

Macquarie Communications Infrastructure Group (MCG) Best Performer of Week 25, 2009


Macquarie Communications Infrastructure Group (MCG), a part of Macquarie Group that owns interests in Broadcast Australia, Arqiva and Airwave was the best performer in the ASX100 index in week 25 followed by Dexus Property Group (DXS), ConnectEast Group (CEU), Common Wealth Property Office Fund (CPA) and Sonic Healthcare (SHL).

Australian Market Preview


Here is an update on the different sectors of Australian market from market analyst Macquarie Research Equities.

Record Oil - The Impact of Black Gold

CSL (CSL) Update


CSL (CSL) has a target price of $42.00 from Australian Stockmarket analyst Macquarie Research Equities.

CSL (CSL)Caution on timing of Cervarix US Approval & we update for FX impact

Delays to Cervarix US approval could be protracted:

Overnight, UBS analysts acknowledged that a 2010 USA launch for GlaxoSmithKline’s cervical cancer vaccine "Cervarix" is at risk. UBSe had previously assumed a 2010 launch, a view "more bearish than consensus" which expected US FDA approval in CY09.

Gardasil monopoly till 2010 a boost to royalties payable to CSL:

CSL Upate


CSL has a maintained 12 month stock price target of $36.95 from Australian sharemarket analyst Macquarie Research Equities.

CSL: A Healthy Alternative

CSL Update


image/jpeg icon
csl-trading-idea.jpg

CSL has a neutral stock recommendation and a share price target of $36.52 from Australian stockmarket analyst Macquarie Research Equities.

CSL: Trading Idea

Baxter International Incorporated (BAX.US), supplier of medical products, reported their quarterly results which were a positive result from CSL’s perspective. Macquarie Research (MRE) maintains their neutral recommendation for CSL stock with a 12 month price target of $36.52. CSL stock traded up 0.8% this morning to $38.12.

CSL – Neutral
Current Price: $38.02
Target Price: $36.52
P/E: 30 X

Best Performing Stocks for the Week 8 of 2008


Perilya (PEM) was the overall best performing stock taking in a 18.9 percent increase in its share price this week. It was a mixture of metal mining, engineering and logistics companies who were among the best performing stocks for the week 8 of 2008 on the Australian stockmarket: Downer EDI (DOW), Oxiana (OXR), CSL (CSL), Perilya (PEM), Boom Logistics (BOL) and Kagara (KZL). These best performing stocks for week 8 of 2008 managed gains above 12 percent by the end of the trading week.

Defensive Stocks for Uncertain Times


I caught a discussion on TV the on Tuesday on the Midday report on the ABC about possible stock picks considering the current global and local economic situation. The expert (sorry didn't catch his name or which firm he was from) said its time to go safe and invest in "defensive stocks" (keyword = invest!)

The newsreader asked him what was his stock picks and here they are - defensive stocks for uncertain times:

  • Australian Securities Exchange (ASX) - because the exchange has a monopoly

CSL Shares


CSL has an unchanged Buy stock recommendation and a share price target of $108.70 from Australian stock analyst UBS. They rate the US IVIG supply as 'marginally adequate'; but short globally: Their FY07 survey coincides with wide ranging global industry meetings which indicate better IVIG availability in the US market relative to the past 12-24mths; industry data suggests distribution 2HFY07 is up 3.7% on pcp. But, supply has not yet returned to 'adequate' levels - measured as 5 weeks supply; any 'hiccup' still spells shortages. Globally, EU remains short & ROW is sporadic at best. US IVIG prices expected to grow c.5% over next 12mths: The analysts' Sep-07 qtr pricing survey shows c.2% US IVIG price gains on consecutive quarters, but up c.10% on pcp for weighted average pricing. CSL has booked the fastest growth, up c.6% on consecutive qtrs to US$52/g; but off the lowest base. Some concentrations of Albumin remains in tight supply & price gains: Albumin at $32/vial (or $2.56/g) is up 14% on pcp; industry expects this to reach c.US$40/vial over the next 12-24mths. Awareness of the SAFE study is very low. Supply gains are consistent with UBSe which show some convergence with demand; they expect a comprehensive supply/demand model will be more critical to sector outlook going forward. There is risk of 'lumpiness' in the market as existing US collection centres gain final approval. But globally, with demand growth put at 7-10%, we continue to rate demand ahead of supply out to end CY10. Their price target is based on FY09 NAV estimate and a DCF analysis of future growth. Read previous CSL shares recommendations.

Syndicate content

E*Trade - $550 FREE Brokerage!